Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program

Wednesday, September 17, 2008 General News J E 4
DUBLIN, Calif., Sept. 17 Microchip Biotechnologies, Inc.(MBI) has been awarded a $625,000 contract under the inaugural US ArmyCommercialization Pilot Program for the development of a Universal SamplePreparation Module (USPM). The Commercialization Pilot Program is a newprogram to assist SBIR firms that have Phase II projects that meet highpriority Army requirements in transitioning to commercial products.

MBI's project will develop a Universal Sample Preparation Module that willautomatically purify DNA from pathogen targets contained in complex matricesto provide samples for various downstream DoD-sponsored analytical platforms.The USPM will enable front-end sample preparation with high specificity forrapid detection, identification, and diagnosis of biological threat agents andwill be applicable to detecting pathogens for molecular diagnostics. UsingMBI's Microscale On-chip Valves (MOV(TM)) technology, the USPM will integratemultiple sample processing steps in a small, universal sample preparationmodule that integrates immunomagnetic separation capture with lysis andnucleic acid purification.

"Easy-to-use sample preparation, under field conditions, has always been amajor obstacle to deploying back end pathogen detection and identificationdevices as well as molecular diagnostics devices. The USPM will greatlysimplify this process and improve detection sensitivity," said Dr. JoanneHorn, Project Manager, heading the USPM development at MBI.

About Microchip Biotechnologies Inc.

Microchip Biotechnologies, Inc. (MBI) is developing the Apollonext-generation fluidics platform for Life Sciences, Applied Sciences, andDiagnostics markets. The Apollo platform incorporates MBI's proprietaryBeadStorm(TM). bead-based sample preparation devices and patented "MicroscaleOn-chip Valves" (MOV(TM)) valves, pumps, and routers on microchips tointegrate, automate, and simplify workflows. The Company's first product, theApollo 100, integrates advanced microfluidic sample preparation to reduce thecost of DNA sequencing. MBI is now adding analytical capabilities to Apolloplatform to create breakthrough sample-to-answer devices for biodefense,DNA-based forensics and human identity (HID), and molecular diagnosticsapplications. MBI is privately held and based in Dublin, California; moredetails can be found on the Company's website:

SOURCE Microchip Biotechnologies, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Yayi International Inc. Reaffirms its Commitment t...
Payless and Shoppers Take Steps in the Fight Again...